February 13, 2024Deleted JournalOpen Access

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22

View Full Paper

Ask AI

Bookmark

Authors

SMScott McCombUniversity of Ottawa MAMehdi Arbabi‐GhahroudiUniversity of Ottawa KHKevin A. HayOccupational Cancer Research Centre

Discussion

Member takes

Implication

Preclinical study demonstrates complete tumor responses from a CD22-targeted nanobody CAR-T therapy in lymphoma xenograft models, highlighting a viable alternative to conventional receptors.

Key Points

A novel nanobody-based chimeric antigen receptor targeting human CD22 mediates potent cytolytic activity, inducing complete tumor clearance in preclinical lymphoma xenografts.
Over 20 single domain antibodies were generated, and lead candidates achieved complete response rates matching benchmark single-chain variable fragments.
Immunohistochemistry and flow cytometry confirmed target selectivity, supporting therapeutic development; mouse xenograft model, further preclinical work needed.

Cite This Study

McComb et al. (2024) studied this question.

synapsesocial.com/papers/68e7956cb6db643587705db8 https://doi.org/10.1016/j.omton.2024.200775

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates complete tumor responses from a CD22-targeted nanobody CAR-T therapy in lymphoma xenograft models, highlighting a viable alternative to conventional receptors.

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22

Discussion

Member takes

Implication

Key Points

Cite This Study

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider